How far can biomarkers take us in neurodegenerative disorders?

It is difficult to miss. The rise and rise of biomarkers in neurodegenerative disorders is seemingly like a juggernaut, unstoppable in its momentum, sweeping all aside in its path. In Alzheimer’s disease, where the project is at its furthest, it has undoubtedly made significant contributions (Frisoni et al., 2017). Biomarker research has galvanized interest in attempts to detect patients at an earlier, prodromal stage; provided selection criteria for clinical trials to reduce heterogeneity within study populations; and potentially begun to assist clinicians in making a diagnosis.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iiHeaq
via IFTTT